Boehringer Ingelheim, a German pharmaceutical company has opened a new scientific office in Nairobi that will serve as its sub-Saharan Africa headquarters.
According to Boehringer Ingelheim India, the Middle East, Turkey, and Africa Regional Managing Director and Head of Human Pharma, Mohammed Tawil said that the new office will help the company expand its presence in the region.
Further, Tawil said the firm is committed to improving human and animal health across Africa.
‘’Our presence here will enable us to better understand the needs of the local communities and work in partnership with healthcare providers and regulators to bring healthcare solutions in areas of unmet medical need,’’ Tawil said.
Moreover, he stated that they are dedicated to making a positive impact on the health and well-being of patients, animals, and communities at large, and they believe that investment in Kenya is an important step towards achieving that goal.
On her part, General Manager and Head of Human Pharma for LINEA and SSA, Marianne Abouelkheir, Boehringer Ingelheim said noted that Sub-Saharan Africa is an important region for Boehringer Ingelheim’s operations.
“Our commitment to excellence and comprehensive understanding of patient needs in the region makes us confident to deliver value across a number of therapeutic areas to tackle diseases such as hypertension and diabetes,’’ he added.
Head of Human Pharma for Sub-Saharan Africa, Marseille Onyango, added that they aim to deliver global best practices and innovative therapies to address the ongoing health requirements of patients and animals locally and across the region.
Boehringer Ingelheim strives to develop better therapies, enable better healthcare solutions, and contribute to a better world for generations to come.
